Angiography and

Economic Aspects. The cardiovascular devices market is estimated to be approximately 2.9 biUion annually on a worldwide basis. This market can be further segmented as follows angiography and angioplasty, 644 x 10 arrhythmia control, 1500 x 10 cardiovascular surgery, 700 x 10 cardiac assist (intra-aortic balloon pump), 80 x 10 and artificial hearts, which are experimental. 

Table 2. Properties of Ionic Monomeric Radiopaques for Angiography and Urography...

Pan XM, Saloner D, Reilly LM, Bowersox JC, Murray SP, Anderson CM, Gooding GA, Rapp JH. Assessment of carotid artery stenosis by ultrasonography, conventional angiography, and magnetic resonance angiography correlation with ex vivo measurement of plaque stenosis. J Vase Surg 1995 21(l) 82-88 [discussion 88-89]. 

Initiate pharmacotherapy for non-ST-segment elevation ACS based upon patient risk evaluate moderate and high-risk patients for early angiography and revascularization... 

Patient symptoms, past medical history, ECG, and troponin or CK-MB determinations are used to stratify patients into low, medium, or high risk of death or MI or likelihood of needing urgent coronary angiography and percutaneous coronary intervention (PCI). 

For patients with NSTE ACS undergoing planned early angiography and revascularization with PCI, UFH, LMWH (enoxaparin), fondaparinux, or bivalirudin should be administered. Therapy should be continued for up to 48 hours for UFH, until the patient is discharged, or a maximum of 8 days for either enoxaparin or fondaparinux, and until the end of the PCI or angiography procedure (or up to 42 hours after PCI) for bivalirudin. 

The pharmacokinetics of X-ray contrast agents used in angiography and urography are practically identical. These are characterized by extracellular distribution followed by renal excretion by glomerular filtration. The terminal half-life is approx. 1.5 h. An overview of the existing data on pharmacokinetics of X-ray contrast media in humans has been given by Bourin et al. [5]. 

A 60-year-old man comes into the office complaining of chest pains that primarily occur in the early morning and do not appear to be associated with stress or exercise. Following coronary angiography and a positive ergonovine test you determine that this patient has angina pectoris as a result of coronary artery spasm. How would you (1) treat the patient to alleviate the acute attacks when they occur and (2) treat chronically to prevent their reoccurrence ... 

Kwok OH, Chow WH, Law TC, et al. First human experience with angiopeptin-eluting stent a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Catheter Cardiovasc Interv2005 66(4) 54l-546. Nakamura M, Wada M, Hara H, et al. Angiographic and clinical outcomes of a pharmacokinetic study of sirolimus-eluting stents lesson from restenosis cases. Circ J 2005 69(10) ... 

Table 3 Three month qualitative coronary angiography and histological analysis...

Kwok OH, Chow WH, Law TC, et al. First human experience with angiopeptin-eluting stent a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Catheter Cardiovasc Interv 2005 66 541-546. 

Ref. (61)]. The interim results confirmed the feasibility and safety of using E2F-I decoy. Analysis of the secondary endpoints using quantitative coronary angiography and three-dimensional intravascular ultrasound demonstrated increased patency and adaptive vessel remodeling characterized by reduction in neointimal size and volume in the treated group one year after treatment, leading to 40% reduction in critical stenosis. These results will now need to be confirmed in adequately sampled and powered phase III studies in patients with coronary and peripheral vessel disease in order to further... 

A meta-analysis was performed on randomized trials assessing lipid-lowering therapy in 698 patients with PAD who were treated with a variety of therapies, including diet, cholestyramine, probucol, and nicotinic acid, for four months to three years (8). There was a significant difference in total mortality [0.7% in the treated patients, as compared with 2.9% in the patients given placebo (p = NS)], with an additional reduction in disease progression, as measured by angiography and the severity of claudication. 

Fang J, Eisenhauer A, Profiles in cardiomyopathy and congestive heart failure, Textbook Grossman s Cardiac Catheterization, Angiography, and Intervention. Seventh Edition, Lippincott Williams Wilkins, 2005. 

Busch E, Beaulieu C, de Crespigny A, Kreischer S, Diener HC, Moseley ME (2002) Combined X-ray angiography and diffusion-perfusion MRI for studying stroke evolution after rt-PA treatment in rats. Brain Res 953 112-118... 

Black Blood Angiography and Vessel Wall Imaging 82 ... 

---